They showed that pre-treatment with recombinant FGF23 impaired acetylcholine (Ach)-induced vasodilatation, which was restored after administration of FGF23 blocking antibodies regardless of the presence of renal failure. The gene discussed is FGF23; the disease is acute kidney injury.